Chondrogene Posts Slight Decline in Q1 Revenue Amid Surge in R&D Spending, Net Loss

May 31, 2006

NEW YORK, May 31 (GenomeWeb News) - Chondrogene's first-quarter revenue declined around 1 percent as R&D spending surged 85 percent and net losses 26.5 percent year over year, the company reported today.

Total receipts for the three months ended March 31 declined to CA$868,222 ($788,312) from CA$878,251 year over year.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Breaking News

The Scan

Prize for Five

Five researchers are to share this year's Albany Medical Center Prize for their work on the CRISPR/Cas9 gene-editing tool, the AP reports.

Sure, Blame the Test

Stat News reports on how white supremacists cope with surprising genetic ancestry testing results.

This Week in Genome Research

In Genome Research this week: sex-biased gene expression evolution in malaria mosquitos, method to find ancient selective sweeps, and more.

Low Down Syndrome Rates in Iceland

Iceland has nearly eliminated Down syndrome from its population, CBS News reports.

Main menu